FDA Panel Supports Baebies' Seeker Newborn Screen Test
The US agency's Clinical Chemistry and Clinical Toxicology Devices panel showed support Aug. 10 for a de novo submission by Baebies Inc. on its Seeker System for newborn screening for lysomal storage disorders. Panelists said the need for the newborn screen outweighed the uncertainties in setting cutoff points and false-positive/false-negative rates.
You may also be interested in...
FDA's increasingly popular de novo classification pathway for moderate-risk devices that have no predicate accounted for five marketing go-aheads last month, four of which were for in vitro diagnostics.
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.
At two recent confirmation hearings, HHS secretary nominee Xavier Becerra promised Senators he would help expand telehealth and procedure price transparency.